Nadia Harbeck, MD, PhD: Interpreting Recent Data on Abemaciclib Plus Endocrine Therapy in Early Breast Cancer

Posted: Thursday, November 30, 2023

Nadia Harbeck, MD, PhD, of Munich’s LMU University Hospital and Ludwig Maximilian University, discusses the recent results of the monarchE trial, in which patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer received adjuvant abemaciclib plus endocrine therapy. Although the overall survival data are not yet mature, benefits continue to grow more than 2 years after completing study treatment. Dr. Harbeck suggests that, instead of using overall survival as an endpoint, a good surrogate may be distant relapse–free survival.